m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05253
 [1], [2]
Non-coding RNA hsa_Circ_0072309 miR-607  lncRNA       miRNA   circRNA Indirect Enhancement m6A modification CD274 CD274 FTO Demethylation : m6A sites
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target Programmed cell death 1 ligand 1 (CD274/PD-L1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa_circ_0072309 (Circ_LIFR) circRNA View Details
Regulated Target hsa-miR-607 View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary Circ_LIFR interacted with hsa-miR-607 via its miRNA response element to upregulate the expression of FTO, an m6A demethylase and downstream target of miR-607, thus promoting tumorigenesis of NSCLC.This study revealed that m6A methylation is closely related to the poor prognosis of non-small cell lung cancer patients via interference with the TIME, which suggests that m6A plays a role in optimizing individualized immunotherapy management and improving prognosis. The expression levels of METTL3, FTO and YTHDF1 in non-small cell lung cancer were changed. Patients in Cluster 1 had lower immunoscores, higher Programmed cell death 1 ligand 1 (CD274/PD-L1) expression, and shorter overall survival compared to patients in Cluster 2. The hallmarks of the Myelocytomatosis viral oncogene (MYC) targets, E2 transcription Factor (E2F) targets were significantly enriched.
Responsed Disease Non-small cell lung cancer ICD-11: 2C25.Y
 Disease Info 
Pathway Response p53 signaling pathway hsa04115
Central carbon metabolism in cancer hsa05230
PD-L1 expression and PD-1 checkpoint pathway in cancer hsa05235
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
CD274 molecule (CD274) 55 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Avelumab Approved [3]
External Link
TTD: D0K7SX
 Compound Name Durvalumab Approved [4]
MOA Modulator
External Link
TTD: D0LS9E
 Compound Name RG-7446 Approved [5]
External Link
TTD: D0OZ4J
 Compound Name Bavencio Approved [6]
MOA Inhibitor
External Link
TTD: D0W8HN
 Compound Name Atezolizumab Approved [7]
External Link
TTD: D0YM2K
 Compound Name Sugemalimab Approved in China [8]
External Link
TTD: DDZ48Y
 Compound Name MEDI4736 Phase 3 [9]
MOA Modulator
External Link
TTD: D04RRZ
 Compound Name MPDL-3280A Phase 3 [10]
MOA Modulator
External Link
TTD: D0Y5IH
 Compound Name CS1001 Phase 3 [11]
External Link
TTD: D3MP1S
 Compound Name A167 Phase 3 [12]
Synonyms
KL-A167
    Click to Show/Hide
External Link
TTD: DI89WD
 Compound Name KN046 Phase 3 [13]
MOA Inhibitor
External Link
TTD: DLOQ25
 Compound Name Pidilizumab Phase 2 [14]
Synonyms
CT-011
    Click to Show/Hide
External Link
TTD: D09MRL
 Compound Name KN035 Phase 2 [15]
Synonyms
Envafolimab
    Click to Show/Hide
External Link
TTD: D0GF2R
 Compound Name CX-072 Phase 2 [16]
MOA Inhibitor
External Link
TTD: D0Z2BO
 Compound Name INCB86550 Phase 2 [17]
MOA Inhibitor
External Link
TTD: DKM79E
 Compound Name Bintrafusp alfa Phase 2 [18]
External Link
TTD: D5J3BL
 Compound Name M7824 Phase 2 [19]
MOA Inhibitor
External Link
TTD: D05FPZ
 Compound Name BGB-A333 Phase 1/2 [20]
External Link
TTD: DC5VW9
 Compound Name GS-4224 Phase 1/2 [21]
Synonyms
Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 12439252
TTD: DS6VD0
 Compound Name NM21-1480 Phase 1/2 [22]
MOA Modulator
External Link
TTD: DUVH60
 Compound Name LY3300054 Phase 1 [19]
External Link
TTD: D08HSS
 Compound Name MSB2311 Phase 1 [15]
External Link
TTD: D0A8AU
 Compound Name Anti-PD-L1 Phase 1 [23]
Synonyms
BMS-936559
    Click to Show/Hide
External Link
TTD: D0KP9A
 Compound Name FAZ053 Phase 1 [16]
MOA Inhibitor
External Link
TTD: D0LU1O
 Compound Name Anti-PD-L1 CSR T cells Phase 1 [24]
MOA CAR-T-Cell-Therapy
External Link
TTD: D0W7UD
 Compound Name BMS-986189 Phase 1 [15]
MOA Inhibitor
External Link
TTD: D0X1GN
 Compound Name Cosibelimab Phase 1 [25]
Synonyms
CK-301/TG-1501
    Click to Show/Hide
External Link
TTD: D17URP
 Compound Name CA-170 Phase 1 [26]
MOA Inhibitor
External Link
TTD: D2Z6WF
 Compound Name PD-L1 t-haNK Phase 1 [27]
External Link
TTD: DH42RF
 Compound Name KD033 Phase 1 [28]
MOA Inhibitor
External Link
TTD: DJVR06
 Compound Name C-Met/PD-L1 CAR-T Cell Phase 1 [29]
MOA CAR-T-Cell-Therapy(Dual specific)
External Link
TTD: D03GTO
 Compound Name CA-170 Phase 1 [19]
Synonyms
3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16212596
TTD: D09PPU
 Compound Name FS118 Phase 1 [15]
External Link
TTD: D0XO9F
 Compound Name PF-07257876 Phase 1 [30]
External Link
TTD: D1A7OP
 Compound Name MCLA-145 Phase 1 [31]
MOA Agonist
External Link
TTD: D2QY0Z
 Compound Name GEN1046 Phase 1 [32]
MOA Agonist
External Link
TTD: D3HBJ1
 Compound Name ALPN-202 Phase 1 [33]
MOA Inhibitor
External Link
TTD: D82UVG
 Compound Name TAK-252 Phase 1 [34]
Synonyms
SL-279252
    Click to Show/Hide
MOA Agonist
External Link
TTD: D9SL1N
 Compound Name INBRX-105 Phase 1 [35]
MOA Inhibitor
External Link
TTD: DA1X5W
 Compound Name LY3415244 Phase 1 [36]
MOA Inhibitor
External Link
TTD: DC8HR6
 Compound Name A337 Phase 1 [12]
External Link
TTD: DL97UQ
 Compound Name IBI318 Phase 1 [37]
MOA Inhibitor
External Link
TTD: DX30BA
 Compound Name PMID30107136-Compound-Example2 Patented [38]
MOA Inhibitor
Activity IC50 = 150 nM
External Link
CID: 117941742
TTD: D0OK1S
 Compound Name PMID30107136-Compound-Example1 Patented [38]
MOA Inhibitor
Activity IC50 = 18 nM
External Link
CID: 117951478
TTD: D0WQ9X
 Compound Name PMID30247903-Compound-General structure7 Investigative [15]
Synonyms
PMID30247903Compound7
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D01TGF
 Compound Name CA-327 Investigative [15]
MOA Inhibitor
External Link
TTD: D04ILU
 Compound Name PMID30247903-Compound-General structure8 Investigative [15]
Synonyms
PMID30247903Compound8
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D04QGF
 Compound Name PMID30247903-Compound-General structure5 Investigative [15]
Synonyms
PMID30247903Compound5
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07BOF
 Compound Name PMID30247903-Compound-General structure12 Investigative [15]
Synonyms
PMID30247903Compound12
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09BYN
 Compound Name PMID30247903-Compound-General structure9 Investigative [15]
Synonyms
PMID30247903Compound9
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0GG6N
 Compound Name PMID30247903-Compound-General structure6 Investigative [15]
Synonyms
PMID30247903Compound6
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0TN4F
 Compound Name PMID30247903-Compound-General structure10 Investigative [15]
Synonyms
PMID30247903Compound10
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0XL3N
 Compound Name YH011 Investigative [39]
External Link
TTD: DA91UG
 Compound Name YH010 Investigative [40]
External Link
TTD: DBTI39
 Compound Name RG6084 Phase 1 [41]
External Link
TTD: DJX7K9
2C25: Lung cancer 52 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Adagrasib Approved [42]
Synonyms
2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
    Click to Show/Hide
External Link
CID: 138611145
TTD: DUQV41
 Compound Name Amivantamab Approved [43]
External Link
TTD: DQ5X1Z
 Compound Name Mobocertinib Approved [44]
Synonyms
1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
    Click to Show/Hide
External Link
CID: 118607832
TTD: DI4HA7
 Compound Name Sugemalimab Approved in China [8]
External Link
TTD: DDZ48Y
 Compound Name Sacituzumab govitecan Approved [45]
Synonyms
1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6
    Click to Show/Hide
External Link
CID: 91668186
TTD: D8LAE2
 Compound Name Atezolizumab Approved [7]
External Link
TTD: D0YM2K
 Compound Name Tepotinib Approved [46]
Synonyms
1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo
    Click to Show/Hide
External Link
CID: 25171648
TTD: D0R8QG
DrugBank: DB15133
 Compound Name Sotorasib Approved [47]
Synonyms
AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-
    Click to Show/Hide
External Link
CID: 137278711
TTD: D0R7LD
DrugBank: DB15569
 Compound Name Entrectinib Approved [48]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Repotrectinib Approved [49]
Synonyms
FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778
    Click to Show/Hide
External Link
CID: 135565923
TTD: D05NFR
 Compound Name MYL-1402O Phase 3 [50]
Synonyms
bevacizumab biosimilar
    Click to Show/Hide
External Link
TTD: DYH3Q6
 Compound Name AB154 Phase 3 [51]
Synonyms
Domvanalimab
    Click to Show/Hide
External Link
TTD: DT1FS0
 Compound Name Datopotamab deruxtecan Phase 3 [52]
External Link
TTD: DP41HV
 Compound Name CS1001 Phase 3 [53]
External Link
TTD: D3MP1S
 Compound Name JDQ443 Phase 3 [54]
Synonyms
(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580
    Click to Show/Hide
External Link
CID: 156501355
TTD: D37IQM
 Compound Name TRS003 Phase 3 [55]
External Link
TTD: D2KVG4
 Compound Name Tusamitamab ravtansine Phase 3 [56]
Synonyms
SAR408701
    Click to Show/Hide
External Link
TTD: D2D6NJ
 Compound Name RG6058 Phase 3 [57]
Synonyms
Tiragolumab
    Click to Show/Hide
External Link
TTD: D0L4VD
 Compound Name GSK4069889 Phase 2 [58]
Synonyms
TSR-022
    Click to Show/Hide
External Link
TTD: DZW53X
 Compound Name APL-101 Phase 2 [59]
Synonyms
Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine
    Click to Show/Hide
External Link
CID: 72202701
TTD: DV3Y7F
 Compound Name SGN-LIV1A Phase 2 [60]
Synonyms
Ladiratuzumab Vedotin
    Click to Show/Hide
External Link
TTD: DS6B1L
 Compound Name BNT116 Phase 2 [61]
External Link
TTD: DR39GZ
 Compound Name AZD7789 Phase 2 [62]
External Link
TTD: DNI7E3
 Compound Name L-DOS47 Phase 1/2 [63]
External Link
TTD: DN3Z5D
 Compound Name NC318 Phase 2 [64]
External Link
TTD: D9UZ5Q
 Compound Name Vorolanib Phase 2 [65]
Synonyms
UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
    Click to Show/Hide
External Link
CID: 59215954
TTD: D8AG3S
DrugBank: DB15247
 Compound Name Xofigo Phase 2 [66]
External Link
TTD: D6B7FP
 Compound Name Bintrafusp alfa Phase 2 [67]
External Link
TTD: D5J3BL
 Compound Name Voyager-V1 Phase 2 [68]
Synonyms
VSV-IFNBeta-NIS
    Click to Show/Hide
External Link
TTD: D4AGB6
 Compound Name AB-106 Phase 2 [69]
Synonyms
DS6051b; GTPL11198; AB106
    Click to Show/Hide
External Link
CID: 154699459
TTD: D2KV8B
 Compound Name RO-5126766 Phase 2 [70]
Synonyms
VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche
    Click to Show/Hide
External Link
CID: 16719221
TTD: D0M6BD
DrugBank: DB15254
 Compound Name TC-210 Phase 1/2 [71]
External Link
TTD: DX6O9V
 Compound Name EMB-01 Phase 1/2 [72]
External Link
TTD: DWQ6J1
 Compound Name NM21-1480 Phase 1/2 [73]
External Link
TTD: DUVH60
 Compound Name MRx0518 Phase 1/2 [74]
External Link
TTD: DP4J2K
 Compound Name DZD9008 Phase 1/2 [75]
External Link
TTD: DM8Y2N
 Compound Name BGB-A425 Phase 1/2 [76]
External Link
TTD: D7UIZ1
 Compound Name Rilvegostomig Phase 1/2 [77]
Synonyms
AZD2936
    Click to Show/Hide
External Link
TTD: D4RMC9
 Compound Name IK-007 Phase 1/2 [78]
Synonyms
grapiprant
    Click to Show/Hide
External Link
TTD: D1KES8
 Compound Name IBI318 Phase 1 [79]
External Link
TTD: DX30BA
 Compound Name GEN-011 Phase 1 [80]
External Link
TTD: DR1YQ7
 Compound Name ENV-105 Phase 1 [81]
Synonyms
Carotuximab
    Click to Show/Hide
External Link
TTD: DQ8K3R
 Compound Name AMG 160 Phase 1 [82]
External Link
TTD: DOY4E6
 Compound Name ADP-A2M10 Phase 1 [83]
External Link
TTD: DM38KC
 Compound Name MEDI5752 Phase 1 [84]
External Link
TTD: D7L1MP
 Compound Name PF-07104091 Phase 1 [85]
External Link
TTD: D5TH2B
 Compound Name PF-06936308 Phase 1 [86]
External Link
TTD: D2LUK7
 Compound Name GEM3PSCA Phase 1 [87]
External Link
TTD: D1L7DE
 Compound Name PF-07257876 Phase 1 [30]
External Link
TTD: D1A7OP
 Compound Name Cosibelimab Phase 1 [88]
Synonyms
CK-301/TG-1501
    Click to Show/Hide
External Link
TTD: D17URP
 Compound Name Gemcitabine Approved [89]
External Link
CID: 60750
TTD: D0AJ3K
DrugBank: DB00441
 Compound Name SMI-4a Investigative [90]
Synonyms
438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione
    Click to Show/Hide
External Link
CID: 1361334
TTD: DAJ3D2
References
Ref 1 Circular RNA hsa_circ_0072309 promotes tumorigenesis and invasion by regulating the miR-607/FTO axis in non-small cell lung carcinoma. Aging (Albany NY). 2021 Apr 20;13(8):11629-11645. doi: 10.18632/aging.202856. Epub 2021 Apr 20.
Ref 2 Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 3 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 5 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
Ref 6 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
Ref 7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 8 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
Ref 9 National Cancer Institute Drug Dictionary (drug id 740856).
Ref 10 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
Ref 11 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608.
Ref 12 Clinical pipeline report, company report or official report of Klus Pharma
Ref 13 Clinical pipeline report, company report or official report of Alphamab Oncology.
Ref 14 PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18. doi: 10.1097/CJI.0b013e31821ca6ce.
Ref 15 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 17 National Cancer Institute Drug Dictionary (drug name INCB086550).
Ref 18 Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Beta and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. doi: 10.1016/j.jtho.2020.03.003. Epub 2020 Mar 13.
Ref 19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 20 Clinical pipeline report, company report or official report of BeiGene.
Ref 21 Clinical pipeline report, company report or official report of Gilead Sciences.
Ref 22 Clinical pipeline report, company report or official report of Numab Therapeutics.
Ref 23 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
Ref 24 ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
Ref 25 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Ref 26 CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804. doi: 10.3390/molecules24152804.
Ref 27 ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
Ref 28 Clinical pipeline report, company report or official report of Kadmon.
Ref 29 ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 30 ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
Ref 31 Clinical pipeline report, company report or official report of Merus.
Ref 32 Clinical pipeline report, company report or official report of Genmab.
Ref 33 Clinical pipeline report, company report or official report of Alpine Immune Sciences.
Ref 34 Clinical pipeline report, company report or official report of Shattuck Labs.
Ref 35 Clinical pipeline report, company report or official report of Inhibrx.
Ref 36 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. doi: 10.1158/1078-0432.CCR-20-3716. Epub 2021 Jan 13.
Ref 37 Clinical pipeline report, company report or official report of Innovent.
Ref 38 A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018). Expert Opin Ther Pat. 2018 Sep;28(9):665-678. doi: 10.1080/13543776.2018.1512706. Epub 2018 Sep 10.
Ref 39 Clinical pipeline report, company report or official report of Biocytogen
Ref 40 Clinical pipeline report, company report or official report of Biocytogen
Ref 41 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 42 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216340.
Ref 43 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761210.
Ref 44 ClinicalTrials.gov (NCT04129502) TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.
Ref 46 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 47 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214665.
Ref 48 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 49 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218213
Ref 50 ClinicalTrials.gov (NCT04633564) Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin?, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT04736173) Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT05555732) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07). U.S.National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT03728556) A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT05132075) A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT04416035) A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC. U.S.National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT04294810) A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01). U.S. National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT04655976) Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung). U.S. National Institutes of Health.
Ref 59 ClinicalTrials.gov (NCT04258033) A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation. U.S. National Institutes of Health.
Ref 60 ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT05557591) A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 >=50%. U.S.National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT04931654) A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
Ref 63 ClinicalTrials.gov (NCT02340208) A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47. U.S. National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT04699123) The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 65 ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
Ref 66 ClinicalTrials.gov (NCT02283749) BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases. U.S.National Institutes of Health.
Ref 67 ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
Ref 69 ClinicalTrials.gov (NCT04395677) A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene. U.S. National Institutes of Health.
Ref 70 ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
Ref 71 ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
Ref 72 ClinicalTrials.gov (NCT03797391) A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
Ref 73 ClinicalTrials.gov (NCT04442126) A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 74 ClinicalTrials.gov (NCT03637803) Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors. U.S. National Institutes of Health.
Ref 75 ClinicalTrials.gov (NCT03974022) Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1). U.S. National Institutes of Health.
Ref 76 ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 77 ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
Ref 78 ClinicalTrials.gov (NCT03696212) Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma. U.S.National Institutes of Health.
Ref 79 ClinicalTrials.gov (NCT04777084) The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.. U.S. National Institutes of Health.
Ref 80 ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
Ref 81 ClinicalTrials.gov (NCT05401110) IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 82 ClinicalTrials.gov (NCT04822298) Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 83 Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
Ref 84 ClinicalTrials.gov (NCT03819465) A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN). U.S. National Institutes of Health.
Ref 85 ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
Ref 86 ClinicalTrials.gov (NCT03674827) Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC. U.S. National Institutes of Health.
Ref 87 ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT04786964) Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO). U.S. National Institutes of Health.
Ref 89 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 90 Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.